Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-06-07
2011-06-07
Li, Bao (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S093100
Reexamination Certificate
active
07955603
ABSTRACT:
The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
REFERENCES:
patent: 5645051 (1997-07-01), Schultz et al.
patent: 5861241 (1999-01-01), Herrmann et al.
patent: 6391318 (2002-05-01), Illum et al.
patent: 6491919 (2002-12-01), Crane
patent: 6572862 (2003-06-01), Estes et al.
patent: 6602697 (2003-08-01), Cook, III
patent: 6942865 (2005-09-01), Estes et al.
patent: 7481997 (2009-01-01), Hardy
patent: 7527801 (2009-05-01), Coit et al.
patent: 2004/0063188 (2004-04-01), Robinson et al.
patent: 2004/0265377 (2004-12-01), Seager
patent: 2005/0154053 (2005-07-01), Rhijn et al.
patent: 2005/0155113 (2005-07-01), Hamilton et al.
patent: 2005/0215501 (2005-09-01), Lipford et al.
patent: 2005/0260225 (2005-11-01), Goldberg et al.
patent: 2007/0207526 (2007-09-01), Coit et al.
patent: 1186890 (2002-03-01), None
patent: WO 92/16543 (1992-10-01), None
patent: WO 2006/136566 (2006-12-01), None
patent: WO 2007/081447 (2007-07-01), None
patent: WO 2009/039229 (2009-03-01), None
Pelosi et al. J. Medical Virology, 1999, vol. 58, pp. 93-99.
Ball et al., Oral Immunization with Recombinant Norwalk Virus-Like Particles Induces a Systemic and Mucosal Immune Response in Mice.Journal of Virology1998; vol. 72(2): 1345-1353.
Estes et al., Norwalk Virus Vaccines: Challenges and Progress.Journal of Infectious Disease2000; vol. 181(Suppl 2): S367-373.
Guerrero et al., Recombinant Norwalk Virus-Like Particles Administered Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune Responses.Journal of Virology2001; vol. 75:9713-9722.
Hansman et al., Genetic and antigenic diversity among Noroviruses.Journal of General Virology2006; vol. 87: 909-919.
Hutson et al., Norovirus disease: changing epidemiology and host susceptibility factors.TRENDS in Microbiology2004; vol. 12(6):279-287.
Johnson et al., Multiple Challenge Study of Host Susceptibility to Norwalk Gastroenteritis in U.S. Adults.The Journal of Infectious Disease1990; vol. 161: 18-21.
Lindesmith et al., Human susceptibility and resistance to Norwalk infection.Nature Medicine2003; vol. 9(5): 548-553.
Lindesmith et al., Cellular and humoral immunity following Snow Mountain virus challenge.Journal of Virology2005; vol. 79(5): 2900-2909.
Lobue et al., Multivalent Norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains.Vaccine2006; vol. 24(24): 5220-5234.
Matsui et al., Immunity to Calicivirus infection.The Journal of Infectious Diseases2000; vol. 181(S2): S331-335.
Mead et al., Food Related Illness and Death in the U.S.Emerging Infectious Diseases1999; vol. 5(5): 607-635.
Nicollier-Jamot et al., Recombinant Virus-like Particles of a Norovirus (Genogroup II Strain) Administered Intranasally and Orally with Mucosal Adjuvants LT and LT(R192G) in BALB/c Mice Induce Specific Humoral and Cellular Th1/Th2-like Immune Responses.Vaccine2004; vol. 22:1079-1086.
Periwal et al., A Modified Cholera Holotoxin CT-E29H Enhances Systemic and Mucosal Immune Responses to Recombinant Norwalk Virus-like Particle Vaccine.Vaccine2003; vol. 21:376-385.
Tacket et al., Humoral, mucosal, and cellular immune response to oral Norwalk virus-like particles in volunteers.Clinical Immunology2003; vol. 108: 241-247.
Ball et al., Recombinant Norwalk virus-like particles given orally to volunteers: phase I study.Gastroenterology1999; vol. 117:40-48.
Parrino et al., Clinical immunity in acute gastroenteritis caused by Norwalk agent.New England Journal of Medicine1977; vol. 297:86-89.
Wyatt et al., Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers.Journal of Infecious. Diseases1974.; vol. 129:709-714.
Baldridge et al., Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration.Vaccine2000; vol. 18:2416-2425.
Baldrick et al., Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant.Regulatory Toxicology and Pharmacology2002; vol. 35:398-413.
Illum et al., Chitosan as a novel nasal delivery system for peptide drugs.Pharmaceutical Research1994.; vol. 11:1186-1189.
Gray et al., Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus.Journal of Clinical Microbiology1994; vol. 32:3059-3063.
Noel et al., Correlation of patient immune responses with genetically characterized small round-structured viruses involved in outbreaks of nonbacterial acute gastroenteritis in the United States, 1990 to 1995.Journal of Medical Virology1997; vol. 53:372-383.
Illum et al., Chitosan as a novel nasal delivery system for vaccines.Advanced Drug Delivery Reviews2001; vol. 51:81-96.
Davis and Illum, Absorption enhancers for nasal drug delivery.Clinical Pharmacokinetics2003; vol. 42:1107-1128.
Illum et al., Nasal drug delivery—possibilities, problems and solutions.Journal of Controlled Release2003; vol. 87:187-198.
Han et al., Immune responses to bovine norovirus-like particles with various adjuvants and analysis of protection in gnotobiotic calves.Vaccine2006; vol. 24:317-326.
Childers et al., “Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen,” Infection and Immunity, vol. 68: 5509-5516, 2000.
Carpenter et al., Rational design of stable lyophilized protein formulations: some practical advice, Pharmaceutical Research, vol. 14: 969-975, 1997.
Malcolmson and Embleton, “Dry powder formulations for pulmonary delivery,” Pharmaceutical Science and Technology Today, vol. 1:394-398, 1998.
Angioni, C.F., “Supplementary European Search Report,” 9 pages, from European Patent Appl. No. 07853688.5, European Patent Office, The Hague, Netherlands (mailed Sep. 22, 2010).
Baric et al., “Expression and Self-Assembly of Norwalk Virus Capsid Protein from Venezuelan Equine Encephalitis Virus Replicons,” J. Virol. 76(6):3023-3030 (2002).
Bertolotti-Ciarlet et al., “Structural Requirements for the Assembly of Norwalk Virus-Like Particles,” J. Virol. 76(8):4044-4055 (2002).
Cao et al., “Structural Basis for the Recognition of Blood Group Trisaccharides by Norovirus,” J. Virol. 81(11):5949-5957 (2007).
Chen et al., “X-ray structure of a native calicivirus: Structural insights into antigenic diversity and host specificity,” Proc. Natl Acad. Sci. USA 103(21):8048-8053 (2006).
Fankhauser et al., “Molecular Epidemiology of “Norwalk-like viruses” in Outbreaks of Gastroenteritis in the United States,” J. Infect. Dis. 178(6):1571-1578 (1998).
Harrington et al., “Systemic, Mucosal, and Heterotypic Immune Induction in Mice Inoculated with Venezuelan Equine Encephalitis Replicons Expressing Norwalk Virus-Like Particles,” J. Virol. 76(2):730-742 (2002).
Herbst-Kralovetz et al., “Norwalk virus-like particles as vaccines,” Exp. Rev. Vaccines 9(3):299-307 (2010).
Huang et al., “Noroviruses Bind to Human ABO, Lewis, and Secretor Histo-Blood Group Antigens: Identification of 4 Distinct Strain-Specific Patterns,” J. Infect. Dis. 188(1):19-31 (2003).
Hutson et al., “Norwalk Virus-Like Particle Hemagglutination by Binding to H Histo-Blood Group Antigens,” J. Virol. 77(1):405-415 (2003).
Jiang et al., “Expression, Self-Assembly, and Antigenicity of the Norwalk Virus Capsid Protein,” J. Virol. 66(11):6527-6532 (1992).
Mason et al., “Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice,” Proc. Natl Acad. Sci. USA 93(11):5335-5340 (1996).
Richardson et al., “
Foubert Thomas R.
Richardson Charles
Tino William T.
Vedvick Thomas S.
Cooley LLP
Li Bao
Ligocyte Pharmaceuticals, Inc.
LandOfFree
Norovirus vaccine formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Norovirus vaccine formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Norovirus vaccine formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2719099